Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Loss of pH control in Plasmodium falciparum parasites subjected to oxidative stress.

van Schalkwyk DA, Saliba KJ, Biagini GA, Bray PG, Kirk K.

PLoS One. 2013;8(3):e58933. doi: 10.1371/journal.pone.0058933. Epub 2013 Mar 11.

2.

Glutathione transport: a new role for PfCRT in chloroquine resistance.

Patzewitz EM, Salcedo-Sora JE, Wong EH, Sethia S, Stocks PA, Maughan SC, Murray JA, Krishna S, Bray PG, Ward SA, Müller S.

Antioxid Redox Signal. 2013 Sep 1;19(7):683-95. doi: 10.1089/ars.2012.4625. Epub 2012 Dec 20.

3.

The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transporters.

Salcedo-Sora JE, Ochong E, Beveridge S, Johnson D, Nzila A, Biagini GA, Stocks PA, O'Neill PM, Krishna S, Bray PG, Ward SA.

J Biol Chem. 2011 Dec 30;286(52):44659-68. doi: 10.1074/jbc.M111.286054. Epub 2011 Oct 13.

4.

Synthesis and antimalarial activities of a diverse set of triazole-containing furamidine analogues.

Berger O, Kaniti A, van Ba CT, Vial H, Ward SA, Biagini GA, Bray PG, O'Neill PM.

ChemMedChem. 2011 Nov 4;6(11):2094-108. doi: 10.1002/cmdc.201100265. Epub 2011 Sep 8.

PMID:
21905228
5.

Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum.

Chaijaroenkul W, Ward SA, Mungthin M, Johnson D, Owen A, Bray PG, Na-Bangchang K.

Malar J. 2011 Feb 15;10:42. doi: 10.1186/1475-2875-10-42.

6.

Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins.

O'Neill PM, Amewu RK, Nixon GL, Bousejra ElGarah F, Mungthin M, Chadwick J, Shone AE, Vivas L, Lander H, Barton V, Muangnoicharoen S, Bray PG, Davies J, Park BK, Wittlin S, Brun R, Preschel M, Zhang K, Ward SA.

Angew Chem Int Ed Engl. 2010 Aug 2;49(33):5693-7. doi: 10.1002/anie.201001026. No abstract available.

PMID:
20629058
7.

An acid-loading chloride transport pathway in the intraerythrocytic malaria parasite, Plasmodium falciparum.

Henry RI, Cobbold SA, Allen RJ, Khan A, Hayward R, Lehane AM, Bray PG, Howitt SM, Biagini GA, Saliba KJ, Kirk K.

J Biol Chem. 2010 Jun 11;285(24):18615-26. doi: 10.1074/jbc.M110.120980. Epub 2010 Mar 23.

8.

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

Janneh O, Bray PG, Jones E, Wyen C, Chiba P, Back DJ, Khoo SH.

J Antimicrob Chemother. 2010 May;65(5):906-16. doi: 10.1093/jac/dkq082. Epub 2010 Mar 17.

9.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A.

Pharmacogenet Genomics. 2010 Feb;20(2):112-20. doi: 10.1097/FPC.0b013e328335b02d.

10.

The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Janneh O, Owen A, Bray PG, Back DJ, Pirmohamed M.

Br J Pharmacol. 2010 Jan 1;159(2):484-93. doi: 10.1111/j.1476-5381.2009.00552.x. Epub 2009 Dec 10.

11.

Plasmodium falciparum and dihydrofolate reductase I164L mutations in Africa.

Alker AP, Juliano JJ, Meshnick SR, Owen A, Ochong E, Bell DJ, Johnson DJ, d'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1722; author reply 1722-3. doi: 10.1128/AAC.01427-08. No abstract available.

12.

Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.

O'Neill PM, Shone AE, Stanford D, Nixon G, Asadollahy E, Park BK, Maggs JL, Roberts P, Stocks PA, Biagini G, Bray PG, Davies J, Berry N, Hall C, Rimmer K, Winstanley PA, Hindley S, Bambal RB, Davis CB, Bates M, Gresham SL, Brigandi RA, Gomez-de-Las-Heras FM, Gargallo DV, Parapini S, Vivas L, Lander H, Taramelli D, Ward SA.

J Med Chem. 2009 Apr 9;52(7):1828-44. doi: 10.1021/jm8012757.

13.

Glycerol: an unexpected major metabolite of energy metabolism by the human malaria parasite.

Lian LY, Al-Helal M, Roslaini AM, Fisher N, Bray PG, Ward SA, Biagini GA.

Malar J. 2009 Mar 6;8:38. doi: 10.1186/1475-2875-8-38.

14.

Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates.

Araújo NC, Barton V, Jones M, Stocks PA, Ward SA, Davies J, Bray PG, Shone AE, Cristiano ML, O'Neill PM.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):2038-43. doi: 10.1016/j.bmcl.2009.02.013. Epub 2009 Feb 8.

PMID:
19251414
15.

Antitumour and antimalarial activity of artemisinin-acridine hybrids.

Jones M, Mercer AE, Stocks PA, La Pensée LJ, Cosstick R, Park BK, Kennedy ME, Piantanida I, Ward SA, Davies J, Bray PG, Rawe SL, Baird J, Charidza T, Janneh O, O'Neill PM.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):2033-7. doi: 10.1016/j.bmcl.2009.02.028. Epub 2009 Feb 11.

PMID:
19249201
16.

Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.

O'Neill PM, Park BK, Shone AE, Maggs JL, Roberts P, Stocks PA, Biagini GA, Bray PG, Gibbons P, Berry N, Winstanley PA, Mukhtar A, Bonar-Law R, Hindley S, Bambal RB, Davis CB, Bates M, Hart TK, Gresham SL, Lawrence RM, Brigandi RA, Gomez-delas-Heras FM, Gargallo DV, Ward SA.

J Med Chem. 2009 Mar 12;52(5):1408-15. doi: 10.1021/jm8012618.

PMID:
19222165
17.

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.

Liptrott NJ, Penny M, Bray PG, Sathish J, Khoo SH, Back DJ, Owen A.

Br J Pharmacol. 2009 Feb;156(3):497-508. doi: 10.1111/j.1476-5381.2008.00050.x. Epub 2009 Jan 20.

18.

Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure.

Ochong E, Bell DJ, Johnson DJ, D'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA, Owen A.

Antimicrob Agents Chemother. 2008 Nov;52(11):3883-8. doi: 10.1128/AAC.00431-08. Epub 2008 Aug 25.

19.

Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex.

Biagini GA, Fisher N, Berry N, Stocks PA, Meunier B, Williams DP, Bonar-Law R, Bray PG, Owen A, O'Neill PM, Ward SA.

Mol Pharmacol. 2008 May;73(5):1347-55. doi: 10.1124/mol.108.045120. Epub 2008 Mar 4.

PMID:
18319379
20.

A comprehensive model of purine uptake by the malaria parasite Plasmodium falciparum: identification of four purine transport activities in intraerythrocytic parasites.

Quashie NB, Dorin-Semblat D, Bray PG, Biagini GA, Doerig C, Ranford-Cartwright LC, De Koning HP.

Biochem J. 2008 Apr 15;411(2):287-95. doi: 10.1042/BJ20071460.

PMID:
18215139
21.

Drug-regulated expression of Plasmodium falciparum P-glycoprotein homologue 1: a putative role for nuclear receptors.

Johnson DJ, Owen A, Plant N, Bray PG, Ward SA.

Antimicrob Agents Chemother. 2008 Apr;52(4):1438-45. doi: 10.1128/AAC.01392-07. Epub 2008 Jan 14.

22.

Malaria-parasite mitochondrial dehydrogenases as drug targets: too early to write the obituary.

Fisher N, Bray PG, Ward SA, Biagini GA.

Trends Parasitol. 2008 Jan;24(1):9-10. Epub 2007 Nov 19. No abstract available.

PMID:
18024199
23.

Prospects for the treatment of drug-resistant malaria parasites.

Tilley L, Davis TM, Bray PG.

Future Microbiol. 2006 Jun;1(1):127-41. Review.

PMID:
17661691
24.

Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs.

Stocks PA, Bray PG, Barton VE, Al-Helal M, Jones M, Araujo NC, Gibbons P, Ward SA, Hughes RH, Biagini GA, Davies J, Amewu R, Mercer AE, Ellis G, O'Neill PM.

Angew Chem Int Ed Engl. 2007;46(33):6278-83. No abstract available.

PMID:
17640025
25.

Study on the biochemical basis of mefloquine resistant Plasmodium falciparum.

Na-Bangchang K, Bray PG, Ward SA.

Exp Parasitol. 2007 Oct;117(2):141-8. Epub 2007 Apr 10.

PMID:
17570363
26.

The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle.

Fisher N, Bray PG, Ward SA, Biagini GA.

Trends Parasitol. 2007 Jul;23(7):305-10. Epub 2007 May 10.

PMID:
17499024
27.

Design and synthesis of orally active dispiro 1,2,4,5-tetraoxanes; synthetic antimalarials with superior activity to artemisinin.

Amewu R, Stachulski AV, Ward SA, Berry NG, Bray PG, Davies J, Labat G, Vivas L, O'Neill PM.

Org Biomol Chem. 2006 Dec 21;4(24):4431-6. Epub 2006 Nov 3. Erratum in: Org Biomol Chem. 2007 Feb 21;5(4):708.

PMID:
17268634
28.

Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp.

Richier E, Biagini GA, Wein S, Boudou F, Bray PG, Ward SA, Precigout E, Calas M, Dubremetz JF, Vial HJ.

Antimicrob Agents Chemother. 2006 Oct;50(10):3381-8.

29.

PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX.

Bray PG, Mungthin M, Hastings IM, Biagini GA, Saidu DK, Lakshmanan V, Johnson DJ, Hughes RH, Stocks PA, O'Neill PM, Fidock DA, Warhurst DC, Ward SA.

Mol Microbiol. 2006 Oct;62(1):238-51. Epub 2006 Aug 31.

30.

A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs.

O'Neill PM, Ward SA, Berry NG, Jeyadevan JP, Biagini GA, Asadollaly E, Park BK, Bray PG.

Curr Top Med Chem. 2006;6(5):479-507. Review.

PMID:
16719804
31.

Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria.

Biagini GA, Viriyavejakul P, O'neill PM, Bray PG, Ward SA.

Antimicrob Agents Chemother. 2006 May;50(5):1841-51.

32.

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.

Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH.

AIDS. 2005 Dec 2;19(18):2097-102.

PMID:
16284458
33.

Quinolines and artemisinin: chemistry, biology and history.

Bray PG, Ward SA, O'Neill PM.

Curr Top Microbiol Immunol. 2005;295:3-38. Review.

PMID:
16265885
34.

Mutations conferring drug resistance in malaria parasite drug transporters Pgh1 and PfCRT do not affect steady-state vacuolar Ca2+.

Biagini GA, Fidock DA, Bray PG, Ward SA.

Antimicrob Agents Chemother. 2005 Nov;49(11):4807-8. No abstract available.

35.
36.

Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum.

Bray PG, Deed S, Fox E, Kalkanidis M, Mungthin M, Deady LW, Tilley L.

Biochem Pharmacol. 2005 Oct 15;70(8):1158-66.

PMID:
16139253
37.

Current drug development portfolio for antimalarial therapies.

Biagini GA, O'Neill PM, Bray PG, Ward SA.

Curr Opin Pharmacol. 2005 Oct;5(5):473-8. Review.

PMID:
16084770
38.

A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance.

Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, Muhle RA, Alakpa GE, Hughes RH, Ward SA, Krogstad DJ, Sidhu AB, Fidock DA.

EMBO J. 2005 Jul 6;24(13):2294-305. Epub 2005 Jun 9.

39.

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.

Owen A, Janneh O, Hartkoorn RC, Chandler B, Bray PG, Martin P, Ward SA, Hart CA, Khoo SH, Back DJ.

J Pharmacol Exp Ther. 2005 Sep;314(3):1202-9. Epub 2005 May 27.

PMID:
15923343
40.

Malaria parasite transporters as a drug-delivery strategy.

Biagini GA, Ward SA, Bray PG.

Trends Parasitol. 2005 Jul;21(7):299-301. Review.

PMID:
15923144
41.

Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria.

Makanga M, Bray PG, Horrocks P, Ward SA.

Proteomics. 2005 May;5(7):1849-58.

PMID:
15832369
42.

Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance.

Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA.

Mol Microbiol. 2005 Apr;56(2):323-33. Review.

43.
44.

Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents.

Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, Sidhu AB, Bray PG, Ward SA.

Mol Cell. 2004 Sep 24;15(6):867-77.

45.

Design and synthesis of endoperoxide antimalarial prodrug models.

O'Neill PM, Stocks PA, Pugh MD, Araujo NC, Korshin EE, Bickley JF, Ward SA, Bray PG, Pasini E, Davies J, Verissimo E, Bachi MD.

Angew Chem Int Ed Engl. 2004 Aug 13;43(32):4193-7. No abstract available.

PMID:
15307085
46.

Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs.

Biagini GA, Pasini EM, Hughes R, De Koning HP, Vial HJ, O'Neill PM, Ward SA, Bray PG.

Blood. 2004 Nov 15;104(10):3372-7. Epub 2004 Jun 17.

PMID:
15205262
47.

Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10beta-(2-hydroxyethyl)deoxoartemisinin.

Jeyadevan JP, Bray PG, Chadwick J, Mercer AE, Byrne A, Ward SA, Park BK, Williams DP, Cosstick R, Davies J, Higson AP, Irving E, Posner GH, O'Neill PM.

J Med Chem. 2004 Feb 26;47(5):1290-8.

PMID:
14971909
48.

Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials.

O'Neill PM, Mukhtar A, Stocks PA, Randle LE, Hindley S, Ward SA, Storr RC, Bickley JF, O'Neil IA, Maggs JL, Hughes RH, Winstanley PA, Bray PG, Park BK.

J Med Chem. 2003 Nov 6;46(23):4933-45.

PMID:
14584944
49.

Antimalarial chemotherapy: young guns or back to the future?

Biagini GA, O'Neill PM, Nzila A, Ward SA, Bray PG.

Trends Parasitol. 2003 Nov;19(11):479-87. Review. No abstract available.

PMID:
14580958
50.

Artemisinins target the SERCA of Plasmodium falciparum.

Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S.

Nature. 2003 Aug 21;424(6951):957-61.

PMID:
12931192

Supplemental Content

Support Center